• Nebivolol hydrochloride in Mechanism-Specific Assays

  2026-09-03

  Nebivolol hydrochloride provides a selective β1-adrenoceptor antagonist tool for separating receptor-proximal cardiovascular signaling from unrelated growth-control pathways. This workflow combines disciplined DMSO handling, β1-adrenergic response assays, and the drug-sensitized yeast platform reported for sensitive TOR inhibitor discovery.

• Indometacin Sodium: Assay Workflows & Tips

  2026-09-03

  Build more interpretable inflammation, differentiation, and proliferation assays with Indometacin Sodium by separating dose response from solvent, viability, and pathway effects. This practical workflow combines COX-focused measurements with disciplined controls inspired by a clinical stroke-mimic investigation.

• RIPA Lysis Buffer (Strong) for Reliable Cell Assays

  2026-09-02

  Learn how RIPA Lysis Buffer (Strong), SKU K1020, can standardize protein extraction after cell viability, proliferation, and cytotoxicity assays. This scenario-driven guide connects formulation, workflow parameters, interpretation, and vendor-selection decisions with practical evidence and literature context.

• Pazopanib Hydrochloride in Cancer Research

  2026-09-02

  Pazopanib Hydrochloride, also called GW786034, is a multi-target receptor tyrosine kinase inhibitor that combines anti-angiogenic activity with broad oncology research utility. Its interpretation requires separation of growth inhibition from actual cell killing, because relative viability and fractional viability measure different drug-response dimensions.

• Mitomycin C Workflows for Apoptosis Research

  2026-09-01

  Mitomycin C combines DNA replication inhibition with strong sensitization potential, making it useful for dose-response, apoptosis, and combination-treatment studies. This practical guide translates its activity in PC3 and colon cancer models into reproducible workflows, controls, and troubleshooting decisions.

• BIRB 796: Reframing p38α Inhibition

  2026-09-01

  BIRB 796 (Doramapimod) offers translational researchers more than potent p38α MAPK inhibition. Its allosteric binding, slow dissociation, kinase selectivity, and potential influence on phosphatase-driven dephosphorylation create a framework for connecting target engagement with cytokine control, apoptosis, and clinical decision-making.

• Reparixin for CXCR1/2 Mechanism Studies

  2026-08-31

  Reparixin enables causal testing of CXCL8–CXCR1/2 signaling in neutrophil migration, inflammatory injury, and emerging tumor–microbe models. This practical guide links assay design, EV-driven oral cancer biology, formulation control, and troubleshooting in one workflow.

• Palomid 529: A Pathway Probe for ESCC Resistance

  2026-08-31

  Palomid 529 (P529) offers a mechanistically focused way to test whether PI3K/Akt/mTOR signaling sustains ESCC metastasis, cisplatin resistance, angiogenesis, or radiation response. This article translates the RCN2–PPP2CA findings into a practical pharmacology and assay strategy without treating P529 as a direct RCN2 inhibitor.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-08-30

  The Annexin V-FITC/PI Apoptosis Assay Kit provides a two-parameter fluorescence assay for separating viable, early apoptotic, and membrane-compromised cells. It is appropriate for research flow cytometry or fluorescence microscopy, but it should not be used as a standalone diagnostic test or as definitive proof of a specific cell-death mechanism.

• CX-5461 RNA Polymerase I Inhibitor Workflow

  2026-08-29

  CX-5461 enables pathway-focused cancer research by linking Pol I transcriptional stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This practical guide covers formulation, cell-based assay design, cisplatin combination studies, in vivo interpretation, and troubleshooting.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-28

  Breen and colleagues developed a genetically drug-sensitized Saccharomyces cerevisiae platform that detects TOR/mTOR pathway inhibitors at substantially lower concentrations than conventional yeast strains. The system distinguished known inhibitors, identified aminophylline as a TOR1-dependent growth inhibitor, and found no evidence of TOR inhibition for several tested compounds, including nebivolol, providing a practical early-stage screening strategy.

• BCA Protein Quantification Kit K4102

  2026-08-28

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 provides sensitive total-protein measurement for dilute samples, including many detergent-containing lysates. It is intended for scientific research and sample normalization, not diagnostic, clinical, or medical testing.

• 0.4% Trypan Blue Solution: Practical Cell QC

  2026-08-27

  0.4% Trypan Blue Solution supports rapid cell viability measurement by differentiating unstained viable cells from blue-stained dead or membrane-damaged cells. It is suitable for research cell counting and cytotoxicity workflows, but it is not a diagnostic test and cannot by itself distinguish apoptosis from necrosis.

• GW 4869 for Exosome Release Workflows

  2026-08-27

  GW 4869 provides a practical chemical perturbation for testing whether neutral sphingomyelinase-dependent vesicle release drives cell-to-cell injury. This guide translates lupus nephritis exosome findings into donor-cell, recipient-cell, cargo, and troubleshooting workflows.

• Palomid 529: PI3K/Akt/mTOR Workflow Guide

  2026-08-26

  Palomid 529 (P529) is a dual mTORC1/mTORC2 pathway probe for connecting tumor-cell signaling, angiogenesis, cisplatin resistance, and radiotherapy response. This practical guide translates its reported potency and formulation limits into assay-ready workflows for cancer research.

8522 records 1/569 page Next 12345 下5页 Last page